ChAdOx1

Publication in Cell Shows That Vaccitech’s SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel “Vax-Innate” Paradigm

Retrieved on: 
星期四, 十月 27, 2022
IND, TLR, SEC, Company, University, Security (finance), U.S. Securities and Exchange Commission, TME, NASDAQ, Private Securities Litigation Reform Act, Publication, Cancer, Disease, Senior, Vaccine, Tumor microenvironment, MVA, Papilloma, Annual report, Oxford University Innovation, Nanoparticle, Drug discovery, Immune system, IV, HPV, Research, COVID-19, GLOBE, Autoimmunity, ChAdOx1, NIH, Jamil Khir Baharom, OUI, Monocyte, Macrophage, AstraZeneca, Cell, Vaccitech

OXFORD, United Kingdom, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the publication of research in preclinical animal models demonstrating the potential of Vaccitech’s SNAPvax for use in a novel paradigm for cancer treatment referred to as “VAX-INNATE.” The results show that intravenous (IV) administration of SNAPvax not only primes and expands tumor-specific cytotoxic T cells that mediate tumor killing but also reverses suppression in the tumor microenvironment associated with significantly improved tumor regression.

Key Points: 
  • The results show that intravenous (IV) administration of SNAPvax not only primes and expands tumor-specific cytotoxic T cells that mediate tumor killing but also reverses suppression in the tumor microenvironment associated with significantly improved tumor regression.
  • The research evaluated SNAPvax co-delivering tumor antigens and a powerful Toll-like receptor (TLR)-7/8 adjuvant by two different routes (IV or subcutaneous) in tumor-bearing mice.
  • The aforementioned research was first published online in Cell and can be accessed at the link in the citation below.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Middle East Respiratory Syndrome (MERS) Drug Pipeline Market Insights Report 2022: 12+ Companies and 12+ Pipeline Drugs in the Pipeline Landscape - ResearchAndMarkets.com

Retrieved on: 
星期二, 十月 4, 2022
Health, Other Health, Vaccine, Vaccitech, News, Middle East respiratory syndrome coronavirus outbreak, Technology, ChAdOx1, Disease, Severe acute respiratory syndrome coronavirus 2, Clinical trial, Middle East respiratory syndrome–related coronavirus, II, NDA, MERS, Antibody, Inovio Pharmaceuticals, Infection, Coronavirus, Discovery, Acquisition, Human coronavirus 229E, DNA, Therapy, Pharmaceutical industry

The "Middle East Respiratory Syndrome - Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Middle East Respiratory Syndrome pipeline landscape.

Key Points: 
  • The "Middle East Respiratory Syndrome - Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Middle East Respiratory Syndrome pipeline landscape.
  • The assessment part of the report embraces, in depth Middle East Respiratory Syndrome commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Middle East Respiratory Syndrome R&D.
  • The companies which have their Middle East Respiratory Syndrome drug candidates in the most advanced stage, i.e.

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

Retrieved on: 
星期一, 十月 3, 2022
MVA, AstraZeneca, University, Cancer, Immune system, OUI, Oxford University Innovation, Autoimmunity, ChAdOx1, COVID-19, Vaccine, Vaccitech

The companys proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax and Syntholytic).

Key Points: 
  • The companys proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax and Syntholytic).
  • The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches.
  • Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI.
  • Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Promotes Gemma Brown as Chief Financial Officer

Retrieved on: 
星期二, 九月 20, 2022
Institute, CFO, ChAdOx1, COVID-19, OUI, EY, Autoimmunity, Oxford University Innovation, Company, Private Securities Litigation Reform Act, Biology, Hotel manager, New Zealand Institute of Chartered Accountants, U.S. Securities and Exchange Commission, University, Cancer, IPO, MVA, Gemma, Finance, Vaccine, AstraZeneca, Annual report, NASDAQ, Security (finance), GLOBE, SEC, Immune system, Pharmaceutical industry, Vaccitech, Nasdaq

OXFORD, United Kingdom, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the promotion of Gemma Brown as Chief Financial Officer (CFO).

Key Points: 
  • OXFORD, United Kingdom, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the promotion of Gemma Brown as Chief Financial Officer (CFO).
  • Gemma has been highly engaged with all financial activities at Vaccitech including working with our auditors, corporate budgeting, SEC financial filings and other activities so we anticipate a seamless transition, said Bill Enright, Chief Executive Officer of Vaccitech.
  • I want to personally thank Georgy for his contributions to Vaccitech particularly his efforts that led to our successful IPO in 2021.
  • Gemma Brown is an experienced financial executive who joined Vaccitech as its Head of Financial Reporting in 2021, before her promotion to CFO.

Vaccitech to Present at Upcoming September Investors Conferences

Retrieved on: 
星期三, 九月 7, 2022
AstraZeneca, University, COVID-19, Oxford University Innovation, Autoimmunity, ChAdOx1, Cancer, Vaccitech, MVA, Immune system, Company, OUI, Security (finance), Vaccine

The companys proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax and Syntholytic).

Key Points: 
  • The companys proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax and Syntholytic).
  • The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches.
  • Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI.
  • Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
星期二, 八月 9, 2022
U.S. Securities and Exchange Commission, GLOBE, SEC, Cancer, Security (finance), Knowledge, Annual report, Patient, Nivolumab, G&A, Infection, HBsAg, Immune system, HPV, Prostate cancer, EASL, Private Securities Litigation Reform Act, Degenerative disease, Oxford University Innovation, VTP, Licensure, Safety, Hepatitis B, Investigational New Drug, OUI, University, Hepatitis, Autoimmunity, HBV, MERS, COVID-19, Program, Vaccine, ChAdOx1, AstraZeneca, Arbutus, Vaccitech, IND, MVA, Company, Human papillomavirus infection, NASDAQ, Research, Insurance, Antigen, EMA, Pharmaceutical industry, Renewable energy

OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Companys recent corporate developments.

Key Points: 
  • OXFORD, United Kingdom, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Companys recent corporate developments.
  • Second Quarter 2022 Financial Highlights:
    Cash position: As of June 30, 2022, cash and cash equivalents were $192.3 million, compared to $214.1 million as of December 31, 2021.
  • Revenues: Revenues were $17.1 million in the second quarter of 2022 compared to $15.0 million in the first quarter of 2022.
  • Research and development expenses: Research and development expenses were $9.7 million in the second quarter of 2022 compared to $10.7 million in the first quarter of 2022.

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

Retrieved on: 
星期四, 七月 7, 2022
EDT, Vaccitech, MVA, Oxford University Innovation, OUI, GLOBE, COVID-19, Cancer, ChAdOx1, Immune system, University, Autoimmunity, AstraZeneca, NASDAQ, Vaccine, Conference

OXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Companys Chief Executive Officer, Bill Enright, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 in New York, July 11 to 12.

Key Points: 
  • OXFORD, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Companys Chief Executive Officer, Bill Enright, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 in New York, July 11 to 12.
  • Mr. Enright will also host one on one meetings with investors at the conference.
  • The webcast of the event will be available starting at 9 a.m. EDT on July 11 and can be accessed through the Events section of the Vaccitech website.
  • Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Retrieved on: 
星期三, 六月 22, 2022
Hepatitis, Population, Security (finance), MVA, Old Road Campus, University of Oxford, Infection, Disease, University, Poxviridae, GLOBE, Poster, Annual report, CHB, ChAdOx1, Oxford University Innovation, Hepatology, Private Securities Litigation Reform Act, Antigen, Degenerative disease, DNA, Immune system, NASDAQ, SEC, Medical school, COVID-19, Knowledge, OXFORD, Nivolumab, OUI, Immune tolerance, Patient, Nuffield Department of Population Health, U.S. Securities and Exchange Commission, Immunotherapy, EASL, AstraZeneca, Chinese University of Hong Kong, Safety, Vaccine, Liver, Company, Cancer, Medical research, Genotype, Faculty, Autoimmunity, HBV, Pharmaceutical industry, Vaccitech, Medicine, HBsAg

OXFORD, United Kingdom, June 22, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases, today announced an update to the interim analysis of safety and efficacy data from the HBV002 study (NCT04778904), which is being presented as a poster at the 2022 EASL International Liver CongressTM by Professor Ellie Barnes, Professor of Hepatology and Experimental Medicine at the University of Oxford.

Key Points: 
  • Meaningful, durable reductions of Hepatitis B surface antigen (HBsAg) were seen in some patients who received VTP-300 as either a monotherapy or in combination with a single low dose of nivolumab at the booster dose.
  • In the VTP-300 monotherapy group, meaningful and durable reductions of HBsAg were seen in all three patients with baseline HBsAg under 50 IU/mL.
  • These three patients had 0.7, 0.7 and 1.4 log10 declines two months after the last dose of VTP-300.
  • These dramatic declines have persisted in all three patients at their latest follow-up at five or eight months after the last dose of VTP-300.

Vaccitech to Present at the Jefferies Healthcare Conference

Retrieved on: 
星期一, 六月 6, 2022
Oxford University Innovation, EDT, Conference, MVA, Vaccitech, University, Vaccine, GLOBE, OUI, Cancer, AstraZeneca, COVID-19, Immune system, NASDAQ, ChAdOx1, Autoimmunity

A live webcast of the presentation can be accessed through the Events section of the Vaccitech website.

Key Points: 
  • A live webcast of the presentation can be accessed through the Events section of the Vaccitech website.
  • Following the live webcast, a replay will be available at the same location.
  • Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI.
  • Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Retrieved on: 
星期一, 六月 6, 2022
Hepatocyte, Hepatitis B, Goal, N-Acetylgalactosamine, CFBV, Therapy, HBV, AstraZeneca, COVID-19, Immune system, Severe acute respiratory syndrome coronavirus 2, PD, Cancer, University, Immunotherapy, Liver cancer, Forward-looking statement, Hepatitis B virus, OUI, Securities Exchange Act of 1934, Cirrhosis, Securities Act of 1933, Antigen, Patient, Poxviridae, World, World Health Organization, Annual report, RNA interference, RNA, Conditional sentence, Vaccine, Virology, Degenerative disease, Oxford University Innovation, Coronavirus, Program, NA, Drug Quality and Security Act, MVA, Nasdaq, GLOBE, Risk, Drug discovery, ChAdOx1, Death, Membrane protein, Safety, Autoimmunity, Pharmaceutical industry, HBsAg, Vaccitech, Arbutus

WARMINSTER, Pa. and OXFORD, U.K., June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Vaccitech plc (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the first patient dosed in a Phase 2a clinical trial. This trial will evaluate Arbutus’ RNAi therapeutic candidate, AB-729, in combination with Vaccitech’s T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NA) therapy for the treatment of patients with virologically-suppressed chronic HBV infection (cHBV).

Key Points: 
  • We are excited to explore these compounds in combination and we look forward to seeing results from this promising study.
  • The randomized, multi-center, blinded, Phase 2a clinical trial will evaluate the safety, antiviral activity and immunogenicity of VTP-300 administered after AB-729 in virologically-suppressed cHBV patients.
  • Clinical data generated thus far has shown single- and multi-doses of AB-729 to be generally safe and well-tolerated while providing meaningful reductions in hepatitis B surface antigen and hepatitis B DNA.
  • Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV).